Pneumococcal Serotype Identification by Capsular Sequence Typing (CST): A Modified Novel Approach for Serotyping Directly in Clinical Samples

Nektarios Marmaras 1, Athanasia Xirogianni 1, Anastasia Papandreou 1, Efthymia Petinaki 2, Vana Papaevangelou 3, Maria Tsolia 4 and Georgina Tzanakaki 1,*

1 National Meningitis Reference Laboratory, Department of Public Health Policy, School of Public Health, University of West Attica, 115 21 Athens, Greece; marmarasn@hotmail.com (N.M.); axirogianni@uniwa.gr (A.X.); npapandreou@uniwa.gr (A.P.)
2 Department of Microbiology, Medical School, University of Thessaly, 411 10 Larissa, Greece; petinaki@med.uth.gr
3 Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital “ATTIKON”, 124 62 Athens, Greece; vpapaev@gmail.com
4 Second Department of Pediatrics, National and Kapodistrian University of Athens, “A&P Kyriakou” Children’s Hospital, 115 27 Athens, Greece; mtsolia@med.uoa.gr
* Correspondence: gtzanakaki@uniwa.gr

Abstract: As almost 60–70% of Invasive Pneumococcal Disease (IPD) is identified by nonculture methods in Greece, serotyping is of high importance for the better monitoring of pneumococcal serotypes due to the availability of conjugate vaccines. The aim of the study was the modification and direct application of the Capsular Sequence Typing (CST) assay in clinical samples in order to serotype Streptococcus pneumoniae culture-negative, Polymerase Chain Reaction (PCR-)-positive samples, followed by CST group specific single-tube PCR assays. A two-step PCR modified assay was applied on a total of 306 samples (such as CSF, blood, pleural and middle ear fluids, isolates) obtained from 283 patients with IPD. The overall performance permits a rapid, accurate and cost-effective method for nonculture pneumococcal serotyping. As the management of IPD is closely related to the continuous monitoring of pneumococcal serotypes, the proposed approach proved to be a valuable tool for the typing and epidemiological monitoring of S. pneumoniae, for the evaluation of the overall impact of vaccination programs in the era of pneumococcal conjugate vaccines, in order to initiate the appropriate vaccination strategy.

Keywords: S. pneumoniae; non-culture serotyping; capsular sequence typing (CST)

1. Introduction

Streptococcus pneumoniae is a major cause of serious bacterial infections including meningitis, septicemia and pneumonia and is associated with significant morbidity and mortality worldwide. Young children and elderly people are at the highest risk, with a high incidence observed in those ages [1].

The ability of S. pneumoniae to cause disease is directly related to the capsule production, a polysaccharide structure external to the cell wall that provides resistance to phagocytosis and promotes the invasion of the host immune system by the bacteria [2]. To date, approximately 100 different pneumococcal serotypes have been identified, based on the unique antigen structure of the capsular polysaccharide, each with their own characteristics, adaptability for nasopharyngeal carriage and potential for invasive disease [3].

Over the years, in order to reduce the burden of Invasive Pneumococcal Disease (IPD), universal infant vaccination schemes have been initiated by initially introducing the 7-valent pneumococcal conjugate vaccine (PCV-7) in the early 2000s. An increase of non-PCV-7 serotypes observed in the following years [4,5] led to the replacement of
PCV-7 in the routine infant immunization schedule. In the early 2010s, two vaccines, the 10-valent pneumococcal conjugate (PCV-10) and the 13-valent pneumococcal conjugate vaccines (PCV-13), offered a wider serotype coverage range [6]. The implementation of PCV universal vaccination has led to a significant decrease of IPD incidence among vaccinated children.

However, as the vaccination is based on the pneumococcal capsular polysaccharides, immunization is expected to put further selective pressure on the pneumococcal population. Important vaccine effects following immunization are serotype replacement and capsule switch. As shown recently, serotypes that are not included in the aforementioned vaccines seem to emerge [7–9].

Consequently, when evaluating the potential impact of current or new vaccines, there is a need to predict the overall benefits, which are influenced by both declines in the disease incidence due to vaccine-targeted serotypes (VTs) and by an increase in the disease incidence due to non-vaccine targeted serotypes (NVTs). Hence, the management of IPD is closely related to the continuous monitoring of pneumococcal serotypes.

*S. pneumoniae* serotyping is usually monitored by the serological determination of the capsular type by standard capsular tests after culture. The gold standard for serotyping is the Quellung or Neufeld test [10,11]. However, the method is time-consuming and expensive. On the other hand, several molecular serotyping methods are described by the use of sequential multiplex Polymerase Chain Reaction (PCR) assays [12–16]. However, due to the large number of pneumococcal serotypes used in order to assess the serotype, several multiplex PCRs are involved. Furthermore, many of the PCR-based serotyping assays, including Restriction Fragment Length Polymorphism (RFLP), Multi Locus Sequence Typing (MLST), DNA microarrays, Next Generation Sequencing (NGS) and Whole Genome Sequencing (WGS), require isolates in order to proceed [17].

On the other hand, Elberse et al. [18], in order to monitor the pneumococcal serotypes in the Netherlands, developed a molecular method, the Capsular Sequence Typing (CST) assay, for serotype identification on pneumococcal isolates. The aforementioned assay was based on the genotyping analysis of the capsular locus *wzh* gene and was achieved by the use of a mix of primers based on publicly available sequences of the capsular genes of known serotypes [19].

As almost 60–70% of *S. pneumoniae* cases are confirmed solely by PCR in Greece—mainly due to the early antibiotic treatment—there is a need for a diagnostic tool for direct serotype identification in culture-negative/PCR-positive biological fluids.

The present study describes a modification of the CST assay in a two-step PCR protocol and its direct application on *S. pneumoniae* culture-negative/PCR-positive clinical samples (CSF, whole blood, pleural fluid, middle ear fluid), which were obtained from patients with IPD clinical manifestations such as meningitis and/or septicemia, pneumonia, as well as otitis media and arthritis (synovial fluids), aiming for a nonculture pneumococcal serotype identification. Further, as the CST method occasionally identifies a group of 2–3 specific serotypes, individual PCR assays were developed and applied in order to define a single serotype.

2. Materials and Methods
2.1. Source of Specimens

A total of 306 samples identified as *S. pneumoniae* were obtained from 283 patients; these included 239 culture-negative PCR-positive clinical samples (whole blood (*n* = 36), cerebrospinal fluid (CSF) (*n* = 118), pleural fluid (*n* = 65), synovial fluid (*n* = 1), middle ear fluid (*n* = 15), blood culture (*n* = 2), pus (*n* = 2)) and 67 pneumococcal isolates. The samples were sent during 2010–2020 from hospitals throughout the country as the routine identification service provided by to the National Meningitis Reference Laboratory (NMRL).

All bacterial isolates received had previously been identified and serotyped with compatible culture methods (α haemolysis, optochin test, Quellung reaction), while the
clinical samples were identified as S. pneumoniae by the use of a multiplex PCR assay described previously [20].

2.2. DNA Isolation

DNA isolation from clinical samples was carried out by the use of the MagCore® Genomic DNA Whole Blood Kit (MagCore HF 16 nucleic acid extraction system, RBC Bioscience, New Taipei City, Taiwan).

For pneumococcal isolates, DNA extraction was carried out from a 24 h blood agar culture, as described previously [20].

2.3. Capsular Sequence Typing (CST)

CST was based on the previously published protocol by Elberse et al. [18]. In order to meet the needs of serotyping directly for clinical samples, the method was modified in a two-step PCR assay. Specifically, during the first step, primers without M-tails were used, while during the second step, the PCR products obtained from the first PCR assay were submitted to the second PCR assay with primers extended with M-tails (i.e., universal forward and reverse sequences added as adapters to the 5′ end upstream and downstream from the oligonucleotides) (Table 1).

Table 1. Primers’ sequences used for the CST protocol.

| Primer       | Primer Sequence                                      | Publication                     |
|--------------|-----------------------------------------------------|--------------------------------|
| CST_1F       | CATTCGCCATATGTTTTTG                                  | Modified from Elberse et al. [18] (without M-tails) |
| CST_2F       | CATTCCTCAATTATTATTTTTGATGT                           |                                |
| CST_3F       | CATTCGCACATGCTTGTGT                                  |                                |
| CST_1R       | CTGAGCTCTTTTTTTCATGA                                |                                |
| CST_2R       | GTGAACITCGTTTCTTCATGA                                |                                |
| CST_3R       | CCGAGCTCTTTTTTTCATAA                                |                                |
| CST_4R       | CCGAGCTCTTTTTTTCATGA                                |                                |
| CST_01-M13F  | GTAAACGCACGCCAG                                      | Elberse et al. [18]            |
|              | CATTCGCCATATGTTTTTG                                  |                                |
| CST_02-M13F  | GTAAACGCACGCCAG                                      |                                |
|              | CATTCCTCAATTATTATTTTTGATGT                           |                                |
| CST_03-M13F  | GTAAACGCACGCCAG                                      |                                |
|              | CATTCGCACATGCTTGTGT                                  |                                |
| CST_01-M13R  | CAGGAAACAGCTATGAC                                   |                                |
|              | CTGAGCTCTTTTTTTCATGA                                |                                |
| CST_02-M13R  | CAGGAAACAGCTATGAC                                   |                                |
|              | GTGAACITCGTTTCTTCATGA                                |                                |
| CST_03-M13R  | CAGGAAACAGCTATGAC                                   |                                |
|              | TATGACCCCACTCTCTTTTCAAA                              |                                |
| CST_04-M13R  | CAGGAAACAGCTATGAC                                   |                                |
|              | TATGACCCCACTCTCTTTTCAAA                              |                                |
| CST sequencing | M13F(-20) GTAAACGCACGCCAG                          |                                |
|              | M13R CAGGAAACAGCTATGAC                              |                                |

During the first step PCR assay, 0.8 mM dNTPs (New England Biolabs, Ipswich, MA, USA), 0.48 U/reaction Phusion®-High Fidelity DNA Polymerase (New England Biolabs,
Ipswich, MA, USA) and 1.1 × HF buffer (New England Biolabs, Ipswich, MA, USA), 0.8 µL primer mix (10 µM/each primer) (VBC, Vienna, Austria) and 2 µL DNA template were mixed in a 20 µL total reaction volume, under the following conditions: 98 °C for 1 min as initial denaturation, 98 °C for 14 s, 58 °C for 35 s and 72 °C for 14 cycles, 98 °C for 13 s, 57 °C for 34 s and 72 °C for 14 cycles, 98 °C for 12 s, 56 °C for 32 s and 72 °C for 35 s for 14 cycles, and 72 °C for 5 min as a final extension step, in a RoboCycler (Stratagene, San Diego, CA, USA). Further, 12 µL of the PCR product were stained with 3 µL GelRed loading buffer (6× Gel loading dye, Biotium, Fremont, CA, USA) subjected to electrophoresis in 2.0% (w/v) agarose gel (Nippon Genetics, Tokyo, Japan) and visualized under ultraviolet fluorescence light.

During the second step PCR protocol, 0.6 mM dNTPs (New England Biolabs, Ipswich, MA, USA), 0.5 U/reaction Phusion®-High Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA, USA), 0.6 µL primer mix (10 µM/each primer) (VBC, Vienna, Austria) and 2 µL DNA template (first PCR product) were added in a 20 µL total reaction volume under the following conditions: 98 °C for 1 min as initial denaturation, 98 °C for 10 sec, 55 °C for 30 s and 72 °C for 20 s for 20 cycles (+0.5 °C/cycle), 98 °C for 10 sec, 66 °C for 30 s and 72 °C for 20 s for 22 cycles, and 72 °C for 5 min as a final extension step, in a PikoThermalCycler (Finnzymes/ThermoFisher Scientific, Waltham, MA, USA). Further, gel electrophoresis was carried out in 5 µL of the PCR product stained with 1 µL GelRed loading buffer (6× Gel loading dye, Biotium, Fremont, California, USA) in 2.0% (w/v) agarose gel (Nippon Genetics, Tokyo, Japan). PCR products were visualized under ultraviolet fluorescence light.

2.4. PCR Product Purification and Sequencing

PCR products were purified according to the PCR-clean-up protocol, NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, Düren, Germany) in a 30 µL final elution volume. Further, in order to test the purification yield, 5 µL of the purified product was stained with 1 µL GelRed loading buffer (6× Gel loading dye, Biotium, Fremont, CA, USA). Purified products were subjected to electrophoresis in 2.0% (w/v) agarose gel (Nippon Genetics, Tokyo, Japan) and visualized under ultraviolet fluorescence light. The purified products were sent for sequencing.

2.5. Sequencing Analysis

Chromatograms were analyzed by the use of Chromas software (http://technelysium.com.au/wp/chromas/, version 2.6.6, Technelysium Pty Ltd, South Brisbane, Australia, free downloaded (accessed on 10 September 2021)). Nucleotide sequences derived from the two DNA chains were compared to each other with ClustalW (https://www.genome.jp/tools-bin/clustalw, Bioinformatics tools provided by GenomeNet, Kyoto University Bioinformatics Center, Kyoto, Japan, free online software (accessed on 10 September 2021)).

The nucleotide sequences were imported in the S. pneumoniae CST Typing Tool (https://www.rivm.nl/mpf/typingtool/spn, version 0.0, National Institute for Public Health and the Environment, Ministry of Health, Welfare and Sport, Catharijnesingel, Utrecht, The Netherlands (accessed on 10 September 2021)) (free online database of the National Institute for Public Health and the Environment, RIVM, Netherlands), and the S. pneumoniae serotype was automatically assigned [18].

2.6. Additional PCR Protocols

For cases in which the CST Typing Tool assigned a group of 2–3 serotypes, for further identification of a single serotype, additional single tube-PCR assays that are currently available were deployed.

The specific primers used are presented in Table 2. All PCR assays were carried out under the same PCR program and reagents’ concentration: 1× Kapa 2G Fast Multiplex mix (Kapa Biosystems, Cape Town, South Africa), 0.3 µM of each respected primer (Table 2) and 2 µL DNA template were mixed in a 20 µL total reaction volume, under the
following conditions: 98 °C for 30 s as initial denaturation, 98 °C for 5 sec, 65 °C for 12 s (−0.2 °C/cycle) and 72 °C for 15 s for 11 cycles, 98 °C for 5 sec, 63 °C for 12 s and 72 °C for 15 s for 27 cycles, and 72 °C for 1 min as a final extension step, in a Piko Thermal Cycler (Finnzymes/Thermo Fisher Scientific, Waltham, MA, USA). PCR products were stained with 3 μL GelRed loading buffer (6× Gel loading dye, Biotium, Fremont, CA, USA), subjected to electrophoresis in 2.0% (w/v) agarose gel (Nippon Genetics, Tokyo, Japan) and visualized under ultraviolet fluorescence light.

Table 2. PCR primers used for the additional single tube PCR assays for the identification of a single serotype among the specific group of serotypes assigned by CST.

| CST-Assigned Serotype | Additional PCR Assays | Product (bp) | Publication |
|-----------------------|-----------------------|--------------|-------------|
| 11A/D, 18F            | 11A-F: GGACATGGTCAGGTTAGTTCCCCAA TATAGT 11A-R: GATTATGAGTTAATTAATTCCAACTTCTCCC 18-F: GCATCTGACATGTGCTTAAT GAGTTGAAG 18-R: CTTAAACATGACTTTTTGTCTTCCCAC | 463 bp | Pai et al. [21] |
| 18                     | 22A/F-F: GAGTAT AGC CAG ATTATGGCAGTT TIAATTGCT 22A/F-R: CTCACGCACGTGCCGCTG GAAACAACAGACAAC | 643 bp | Pai et al. [21] |
| 22A/F, 15B/C           | 22F-F: CTITGGAATTTTTTAATTAGTGGCTTACC CTA 22F-R: GCATCTGACATGTGCTTAAT GAGTTGAAG 22A-F: CCCAGGACAATCAACAGAAACTA 22A-R: TGATGCTTGGCACAATTTGGAG | 82 bp | Velusamy et al. [22] |
| 15B/C, 23F             | 15B/C-F: TTTGGAATTTTTTAATTAGTGGCTTACC CTA 15B/C-R: CATCCGCGATTTAATT GAAATGCATTCAAGACC 23F-F: TGCTGTAATGACACAAGCAGA 23F-R: CAAAAGCATTGCGTCAATGATC | 496 bp | Pai et al. [21] |
| 12F/B, 44              | 12F/44-F: TCGGAGGGCTCGGATTTATTATTG 12F/44-R: CTTGGTAATCCACTTGTCTTGG | 149 bp | Velusamy et al. [22] |
| 20, 13                 | 20-F: GAG CAA GAG TTT TTC ACC TGA CAG CGA GAA G 20-R: CTA AAT TCC TGT AAT TTA GCT AAA ACT CTTATC 13-F: TACTAA GGAAT CTTCGGAAAGG 13-R: CTCATGCATTITAT AACCCTT CTTG TTC | 514 bp | Pai et al. [21] |
| 20                     | 13-F: TACTAA GGAAT CTTCGGAAAGG 13-R: CTCATGCATTITAT AACCCTTT CTTG TTC | 655 bp | Da Gloria Carvalho [24] |

2.7. Specificity

The specificity of the CST method was assessed from the 67 pneumococcal isolates of the known serotype by the Quellung reaction sent by the hospitals.
3. Results

Capsular Sequence Typing (CST)

The CST was shown to be well-performed in all clinical samples \((n = 239)\) (whole blood samples, CSF pleural/middle ear/synovial fluids, blood cultures) and bacterial isolates \((n = 67)\) identified previously by PCR as *S. pneumoniae*. As the same serotype was identified in two or more samples obtained from the same patient, one serotype was considered per patient/case in the present study.

The specificity was estimated at 100% and evaluated from the 67 *S. pneumoniae* isolates for which the serotype was identified by the Quellung reaction (PPV 100% and NPV 100%).

The CST successfully directly identified a single serotype (or a pair of serotypes within the same group) in 49.12% of the cases \((139/283)\); namely, serotypes 3, 7A/F, 8, 9N/L, 10A, 10B, 10F/C, 14, 15A, 16F, 18A, 19A, 21, 23A, 23B, 31, 37 and 42 (Table 3).

| CST-Assigned Serotype | Final Serotype Identified | Number of Cases |
|-----------------------|---------------------------|-----------------|
| 3                     | 3                         | 45              |
| 8                     | 8                         | 18              |
| 10A                   | 10A                       | 2               |
| 10B                   | 10B                       | 1               |
| 14                    | 14                        | 3               |
| 15A                   | 15A                       | 11              |
| 16F                   | 16F                       | 2               |
| 18A                   | 18A                       | 1               |
| 19A                   | 19A                       | 15              |
| 21                    | 21                        | 8               |
| 23A                   | 23A                       | 15              |
| 23B                   | 23B                       | 5               |
| 31                    | 31                        | 2               |
| 37                    | 37                        | 2               |
| 42                    | 42                        | 2               |
| 7A/F                  | 7A/F                       | 2               |
| 9N/L                  | 9N/L                       | 4               |
| 10F/C                 | 10F/C                       | 1               |
| **TOTAL**             |                           | **139 (49.12%)**|

Table 3. Pneumococcal single serotype identification by the application of CST.

For the remaining cases, for which CST assigned a group of two or three serotypes, the further application of an additional CST-assigned group specific single-tube PCR assay with the use of previously published primers pairs was deployed. According to the results, the CST-assigned group specific single-tube PCR assay successfully further identified a single serotype in 31.44% \((89/283)\) of cases as follows: serotype 11A/D (previously CST-assigned as a group of serotypes 11A/D, 18F); serotype 12F (previously CST-assigned as 12F/B); serotype 22F (previously CST-assigned as 22A/F,15B/C); serotype 15B/C (previously CST-assigned as 15B/C,23F) and serotype 20 (previously CST-assigned as 20,13) (Table 4).
Table 4. Pneumococcal serotype identification by the application of CST in combination with specific single-tube PCR assays.

| CST-Assigned Serotype | Single PCR Assays | Final Serotype Identified | Number of Cases |
|-----------------------|-------------------|---------------------------|-----------------|
| 11A/D, 18F           | 11A/D             | 11A/D                     | 18              |
| 12F/B                 | 12F/44            | 12F                       | 14              |
| 15B/C, 23F           | 15B/C, 23F        | 15B/C, 23F                | 28              |
| 20,13                 | 20,13             | 20,13                     | 7               |
| 22A/F, 15B/C         | 22A/F, 15B/C      | 22A/F, 15B/C              | 22              |
| TOTAL                 |                   |                           | 89 (31.44%)     |

Finally, for 55/283 (19.4%) of the remaining cases for which the serotypes were CST-assigned in the following specific groups, 17A/35B/C, 24F/40, 25A/F/38, 33A/F/35A, 34/17A, 35F/47F, there was no possibility for a single serotype to be identified due to a lack of PCR assays being currently available (Table 5).

Table 5. Pneumococcal serotype identification by the application of CST assigning two or two serotypes.

| CST-Assigned Serotype | Single PCR Assays | Final Serotype Identified | Number of Cases |
|-----------------------|-------------------|---------------------------|-----------------|
| 24F/40                | NA *              | 24F/40                    | 18              |
| 25A/F, 38             | NA                | 25A/F, 38                 | 7               |
| 33A/F, 35A            | NA                | 33A/F, 35A                | 3               |
| 34/17A                | NA                | 34, 17A                   | 5               |
| 35F/47F               | NA                | 35F/47F                   | 7               |
| TOTAL                 |                   |                           | 55 (19.4%)      |

* NA: Not Assigned; single-tube specific PCR assays not currently available.

4. Discussion

The bacteriological confirmation and serotype determination of clinically suspected IPD is important for a detailed epidemiological surveillance of pneumococcal infections. As has been recently shown, the incidence of serotypes responsible for IPD can change overtime [8]. Taking into consideration vaccine pressure and the development of future conjugate vaccines, the continuous monitoring of serotypes is important in the era of pneumococcal conjugate vaccines.

The necessity to understand serotypes’ specific epidemiology and their association with the disease types, the difficulties which are currently faced in the management of pneumococcal disease and the adoption of preventive measures has led to further research on nonculture pneumococcal capsular typing techniques. As more than 60% of the S. pneumoniae cases are currently identified by molecular methods, the need for molecular identification and typing into clinical samples directly has been increasing in recent years.
It is well known that the gold standard for serotyping is the Quellung or Neufeld test; however, the method is time-consuming and not cost-effective as the type, group and factor sera are expensive and require bacterial isolates. On the other hand, taking into account that approximately 100 different pneumococcal capsular types currently exist, the molecular approach by the use of sequential multiplex PCR assays [12,25] and real-time PCR methods [26–29], although it allows the serotype identification of culture-negative PCR-positive clinical samples at a high percentage (75–90%), still remains time-consuming and expensive.

Hence, in order to be able to identify the prevalent serotypes, there is a need for less time-consuming, more cost-effective assays, especially during the post-PCV-13 era, during which serotype diversity has generally increased, with diverse serotypes such as 24F, 22F, 8, 15A and 33F becoming important in countries that use PCV-13 [30,31].

The present study demonstrates that the direct application of the CST in clinical samples identified all 239 nonculture clinical samples. The majority (80.56%) of cases assigned a single serotype, either solely by CST or in combination with single-tube PCR assays targeting for a specific CST group. The application of a two-step PCR protocol improved the yield of the PCR product, creating a sensitive tool when applied directly to clinical samples. As a result, a single serotype was identified directly by CST, without discrepancies in almost 50% of the cases, while the further application of the CST group specific single-tube PCR assay targeting a group of 2–3 serotypes yielded an additional 31.4% single serotypes.

There was a 100% correlation with the results obtained by the use of traditional serotyping methods for the 67 culture-confirmed cases in which the serotype was identified.

In comparison to serotype identification performed by either conventional methods (Quellung) or by the application of sequential multiplex PCR assays, the proposed methodology provides the typing of nonculture samples in a relatively inexpensive, rapid (results can be obtained within 24 h) and reliable way by the direct identification of a single serotype or identification of a group of two or three serotypes, which can be further identified by single-tube PCR assay. Further, the proposed methodology is rather conventional and can be easily established in laboratories that are equipped for DNA template preparation and PCR. Sequencing apparatus is not essential as it can be carried out by an external laboratory.

5. Conclusions

The application of the proposed methodology for direct pneumococcal serotyping to culture-negative, PCR-positive clinical samples is relatively inexpensive, rapid and reliable and could ameliorate pneumococcal serotype surveillance. Furthermore, it may facilitate the close monitoring of evolving serotypes and vaccine effectiveness, which is crucial for the evaluation of the overall impact of pneumococcal vaccination programs and for designing future vaccination strategies.

Author Contributions: Conceptualization: N.M., A.X. and G.T.; formal analysis: N.M., A.X. and G.T.; funding acquisition: G.T.; investigation: N.M., A.X., A.P. and G.T.; methodology: N.M., A.X., A.P. and G.T.; project administration: A.X. and G.T.; resources: A.X. and G.T.; software: N.M. and A.X.; supervision: A.X. and G.T.; validation: N.M., A.X., A.P. and G.T.; visualization: N.M., A.X., A.P., E.P., VP, M.T. and G.T.; writing original draft: A.X. and N.M.; writing review and editing: A.X., G.T., E.P., VP. and M.T. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded by the National Organization of Public Health (EODY) in the framework of the annual financial support to the National Meningitis Reference Laboratory.

Institutional Review Board Statement: Ethical review and approval were waived in this study as the procedures being performed were part of the routine laboratory diagnosis and surveillance of bacterial meningitis. The study was conducted in accordance with the 1964 Helsinki Declaration and its latter amendments or comparable ethical standards.
Informed Consent Statement: Patient consent was waived due to depersonalized data from a notifiable disease registry, and laboratory findings were used.

Data Availability Statement: Not applicable.

Acknowledgments: The authors are grateful to all collaborative clinicians and microbiologists from hospitals throughout the country for sending samples.

Conflicts of Interest: No financial or other conflict of interest is to be reported.

References

1. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2000, 49, 1–35.

2. De Velasco, E.A.; Verheul, A.F.; Verhoef, J.; Snippe, H. Streptococcus pneumoniae: Virulence factors, pathogenesis, and vaccines. Microbiol. Rev. 1995, 59, 591–603.

3. Greenberg, D.; Hoover, P.A.; Vesikari, T.; Peltier, C.; Hurley, D.C.; McFetridge, R.D.; Dallas, M.; Hartzel, J.; Marchese, R.D.; Coller, B.-A.G.; et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 2018, 36, 6883–6891. [CrossRef]

4. Richter, S.S.; Heilmann, K.P.; Dohrn, C.L.; Riahi, F.; Diekema, D.; Doern, G.V. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg. Infect. Dis. 2013, 19, 1074–1083. [CrossRef]

5. Maraki, S.; Samonis, G.; Galanakis, E. Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29, 1449–1451.

6. Johnson, H.L.; Deloria-Knoll, M.; Levine, O.S.; Stoszek, S.K.; Freimanis Hance, L.; Reithinger, R.; Muenz, L.R.; O’Brien, K.L. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: The pneumococcal globalserotype project. PLoS Med. 2010, 7, e1000348. [CrossRef] [PubMed]

7. Van der Linden, M.; Perniciaro, S.; Imohl, M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015, 15, 207. [CrossRef]

8. Amin-Chowdhury, Z.; Collins, S.; Sheppard, C.; Litt, D.; Fry, N.K.; Andrews, N.; Ladhani, S.N. Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014–2018. Clin. Infect. Dis. 2020, 71, e235–e243. [CrossRef] [PubMed]

9. Garcia Quesada, M.; Yang, Y.; Bennett, J.C.; Hurley, D.C.; McFetridge, R.D.; Dallas, M.; Hartzel, J.; Marchese, R.D.; Coller, B.-A.G.; et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine 2018, 36, 6883–6891. [CrossRef]

10. Austrian, R. The quellung reaction, a neglected microbiologic technique. Mt. Sinai J. Med. 1976, 43, 699–709. [PubMed]

11. Lund, E. Laboratory diagnosis of Pneumococcus infections. Bull. World Health Organ. 1960, 23, 5–13. [PubMed]

12. Brito, D.A.; Ramirez, M.; de Lencastre, H. Serotyping Streptococcus pneumoniae by Multiplex PCR. J. Clin. Microbiol. 2003, 41, 2378–2384. [CrossRef] [PubMed]

13. Kong, F.; Gilbert, G.L. Using cpsA-cpsB sequence polymorphisms and serotype-/group-specific PCR to predict 51 Streptococcus pneumoniae capsular serotypes. J. Med. Microbiol. 2003, 52, 1047–1058. [CrossRef] [PubMed]

14. Kong, F.; Wang, W.; Tao, J.; Wang, L.; Wang, Q.; Sabanathan, A.; Gilbert, G.L. A molecular-capsular-type prediction system for 90 Streptococcus pneumoniae serotypes using partial cpsA-cpsB sequencing and wzy- or wzx-specific PCR. J. Med. Microbiol. 2005, 54, 351–356. [CrossRef]

15. Dias, C.; Teixeira, L.M.; Carvalho, M.D.G.; Beall, B. Sequential multiplex PCR for determining capsular serotypes of pneumococci recovered from Brazilian children. J. Med. Microbiol. 2007, 56, 1185–1188. [CrossRef]

16. Morais, L.; Carvalho, M.D.G.; Roca, A.; Flannery, B.; Mandomando, I.; Soriano-Gabarro, M.; Sigauque, B.; Alonso, P.L.; Beall, B. Sequential multiplex PCR for identifying pneumococcal capsular serotypes from South-Saharan African clinical isolates. J. Med. Microbiol. 2007, 56 Pt. 9, 1181–1184. [CrossRef]

17. Geno, K.A.; Gilbert, G.L.; Song, J.Y.; Skovsted, I.C.; Klugman, K.P.; Jones, C.; Konradsen, H.B.; Nahm, M.H. Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin. Microbiol. Rev. 2015, 28, 871–899. [CrossRef]

18. Elberse, K.E.; van de Pol, I.; Witteveen, S.; van der Heide, H.G.; Schot, C.S.; van Dijk, A.; van der Ende, A.; Schouls, L.M. Population structure of invasive Streptococcus pneumoniae in The Netherlands in the pre-vaccination era assessed by MLVA and Capsular Sequence Typing. PLoS ONE 2011, 6, e20390. [CrossRef]

19. Bentley, S.D.; Aanesen, D.M.; Mavroidi, A.; Saunders, D.; Rabbinowitsch, E.; Collins, M.; Donohoe, K.; Harris, D.; Murphy, L.; A Quail, M.; et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2006, 2, e31. [CrossRef]

20. Tzanakaki, G.; Tsapanomichalou, M.; Kesanopoulos, K.; Matzourani, R.; Sioumala, M.; Tabaki, A.; Kremastinou, J. Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae. Clin. Microb. Infect. 2005, 11, 386–390. [CrossRef]
21. Pai, R.; Gertz, R.E.; Beall, B. Sequential multiplex PCR approach for determining capsular serotypes of *Streptococcus pneumoniae* isolates. *J. Clin. Microbiol.* 2006, 44, 124–131. [CrossRef] [PubMed]

22. Velusamy, S.; Tran, T.; Mongkoltrattanothai, T.; Walker, H.; McGee, L.; Beall, B. Expanded sequential quadruplex real-time polymerase chain reaction (PCR) for identifying pneumococcal serotypes, penicillin susceptibility, and resistance markers. *Diagn. Microbiol. Infect Dis.* 2020, 97, 115037. [CrossRef] [PubMed]

23. Lawrence, E.R.; Griffiths, D.B.; Martin, S.A.; George, R.C.; Hall, L.M. Evaluation of semi-automated multiplex PCR assay for determination of *Streptococcus pneumoniae* serotypes and serogroups. *J. Clin. Microbiol.* 2003, 41, 601–607. [CrossRef] [PubMed]

24. Carvalho, M.D.G.; Pimenta, F.C.; Jackson, D.; Roundtree, A.; Ahmad, Y.; Millar, E.V.; O’Brien, K.; Whitney, C.G.; Cohen, A.L.; Beall, B.W. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. *J. Clin. Microbiol.* 2010, 48, 1611–1618. [CrossRef]

25. Azzari, C.; Moriondo, M.; Indolfi, G.; Massai, C.; Becciolini, L.; de Martino, M.; Resti, M. Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by *Streptococcus pneumoniae* in Italian children. *J. Med. Microbiol.* 2008, 57, 1205–1212. [CrossRef] [PubMed]

26. Azzari, C.; Moriondo, M.; Indolfi, G.; Cortimiglia, M.; Canessa, C.; Becciolini, L.; Lippi, F.; de Martino, M.; Resti, M. Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease. *PLoS ONE.* 2010, 5, e9282. [CrossRef] [PubMed]

27. Marchese, A.; Esposito, S.; Coppo, E.; Rossi, G.A.; Tozzi, A.; Romano, L.; da Dalt, G.; Schito, C.; Principi, N. Detection of *Streptococcus pneumoniae* and identification of pneumococcal serotypes by real-time polymerase chain reaction using blood samples from Italian children ≤ 5 years of age with community-acquired pneumonia. *Microb. Drug Resist.* 2011, 17, 419–424. [CrossRef]

28. Blaschke, A.J.; Heyrend, C.; Byington, C.; Obando, I.; Vazquez-Barba, I.; Doby, E.H.; Korgenski, E.K.; Sheng, X.; Poritz, M.A.; Daly, J.A.; et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. *Pediatr. Infect. Dis. J.* 2011, 30, 289–294. [CrossRef]

29. Magomani, V.; Wolter, N.; Tempia, S.; du Plessis, M.; de Gouveia, L.; von Gottberg, A. Challenges of using molecular serotyping for surveillance of pneumococcal disease. *J. Clin. Microbiol.* 2014, 52, 3271–3276. [CrossRef] [PubMed]

30. Tin Tin Htar, M.; Christopoulou, D.; Schmitt, H.J. Pneumococcal serotype evolution in Western Europe. *BMC Infect. Dis.* 2015, 15, 419. [CrossRef]

31. Amin-Chowdhury, Z.; Groves, N.; Sheppard, C.L.; Litt, D.; Fry, N.K.; Andrews, N.; Ladhani, S.N. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes. *Vaccine* 2021, 39, 1997–2004. [CrossRef] [PubMed]